title: The risky business of dopamine agonists in Parkinson disease and impulse control disorders.
abstract: Risk-taking behavior is characterized by pursuit of reward in spite of potential negative consequences. Dopamine neurotransmission along the mesocorticolimbic pathway is a potential modulator of risk behavior. In patients with Parkinson's disease (PD), impulse control disorder (ICD) can result from dopaminergic medication use, particularly dopamine agonists (DAA). Behaviors associated with ICD include hypersexuality as well as compulsive gambling, shopping, and eating, and these behaviors are potentially linked to alterations to risk processing. Using the Balloon Analogue Risk Task, we assessed the role of agonist therapy on risk-taking behavior in PD patients with (n = 22) and without (n = 19) active ICD symptoms. Patients performed the task both "on" and "off" DAA. DAA increased risk-taking in PD patients with active ICD symptoms, but it did not affect risk behavior of PD controls. DAA dose was also important in explaining risk behavior. Both groups similarly reduced their risk-taking in high compared to low risk conditions and following the occurrence of a negative consequence, suggesting that ICD patients do not necessarily differ in their abilities to process and adjust to some aspects of negative consequences. Our findings suggest dopaminergic augmentation of risk-taking behavior as a potential contributing mechanism for the emergence of ICD in PD patients.
authors: Department of Neurology.
authors: Daniel O
authors: DO
authors: Claassen
authors: Department of Psychology, University of Amsterdam.
authors: Wery P M
authors: WPM
authors: van den Wildenberg
authors: Department of Psychology, University of Amsterdam.
authors: K Richard
authors: KR
authors: Ridderinkhof
authors: Department of Neurology.
authors: Charles K
authors: CK
authors: Jessup
authors: Department of Neurology.
authors: Madaline B
authors: MB
authors: Harrison
authors: Department of Neurology.
authors: G Frederick
authors: GF
authors: Wooten
authors: Scott A
authors: SA
authors: Wylie
references: Behav Brain Res. 2009 Jun 8;200(1):48-59
references: 19162084
references: J Psychiatr Res. 1975 Nov;12(3):189-98
references: 1202204
references: Neurology. 2006 Oct 10;67(7):1258-61
references: 17030761
references: Mayo Clin Proc. 2009 Apr;84(4):310-6
references: 19339647
references: Assessment. 2005 Dec;12(4):416-28
references: 16244122
references: Neurology. 2006 Oct 10;67(7):1254-7
references: 16957130
references: Neuropsychologia. 2000;38(5):596-612
references: 10689037
references: Psychopharmacology (Berl). 2010 Aug;211(2):209-21
references: 20495787
references: Brain Cogn. 2009 Dec;71(3):354-61
references: 19679384
references: Addiction. 1999 Mar;94(3):371-83
references: 10605866
references: Science. 2003 Mar 21;299(5614):1898-902
references: 12649484
references: Science. 2004 Dec 10;306(5703):1940-3
references: 15528409
references: Brain. 2009 May;132(Pt 5):1376-85
references: 19346328
references: Neuropsychopharmacology. 2009 Dec;34(13):2758-66
references: 19741594
references: Proc Natl Acad Sci U S A. 2002 Dec 24;99(26):17113-8
references: 12482941
references: J Neural Transm (Vienna). 2003 Nov;110(11):1289-301
references: 14628193
references: Neuroimage. 2008 Aug 15;42(2):902-10
references: 18582578
references: Neurology. 2010 Nov 9;75(19):1711-6
references: 20926784
references: Ann N Y Acad Sci. 2008 Apr;1128:53-62
references: 18469214
references: Curr Opin Neurol. 2007 Aug;20(4):484-92
references: 17620886
references: N Engl J Med. 1988 Apr 7;318(14):876-80
references: 3352672
references: Cereb Cortex. 2001 Dec;11(12):1136-43
references: 11709484
references: J Pers. 1972 Sep;40(3):483-501
references: 5069800
references: J Adolesc. 2003 Aug;26(4):475-9
references: 12887935
references: J Clin Child Adolesc Psychol. 2007 Mar;36(1):106-11
references: 17206886
references: Exp Clin Psychopharmacol. 2003 Feb;11(1):26-33
references: 12622341
references: PLoS One. 2008 Jun 25;3(6):e2479
references: 18575579
references: J Exp Psychol Appl. 2002 Jun;8(2):75-84
references: 12075692
references: Brain. 1991 Oct;114 ( Pt 5):2283-301
references: 1933245
references: Mov Disord. 2007 Sep 15;22(12):1757-63
references: 17580327
references: Arch Neurol. 2006 Jul;63(7):969-73
references: 16831966
references: Arch Neurol. 2005 Sep;62(9):1377-81
references: 16009751
references: J Neurol Neurosurg Psychiatry. 1992 Mar;55(3):181-4
references: 1564476
references: Mov Disord. 2009 Jul 30;24(10):1461-7
references: 19452562
references: Psychopharmacology (Berl). 2007 Apr;191(3):391-431
references: 17072591
references: Neuron. 2010 Jan 14;65(1):135-42
references: 20152119
references: Int Rev Psychiatry. 2008 Aug;20(4):364-73
references: 18925485
references: Mov Disord. 2004 Apr;19(4):397-405
references: 15077237
references: Mov Disord. 2010 Aug 15;25(11):1660-9
references: 20589879
references: Drug Alcohol Depend. 2005 Apr 4;78(1):83-90
references: 15769561
references: Arch Neurol. 2010 May;67(5):589-95
references: 20457959